Parisa Momtaz

4.9k total citations · 1 hit paper
40 papers, 1.8k citations indexed

About

Parisa Momtaz is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Parisa Momtaz has authored 40 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 16 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Parisa Momtaz's work include Cancer Immunotherapy and Biomarkers (27 papers), CAR-T cell therapy research (20 papers) and Melanoma and MAPK Pathways (13 papers). Parisa Momtaz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), CAR-T cell therapy research (20 papers) and Melanoma and MAPK Pathways (13 papers). Parisa Momtaz collaborates with scholars based in United States, Indonesia and Spain. Parisa Momtaz's co-authors include Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok, Paul B. Chapman, Katherine S. Panageas, Richard D. Carvajal, Troy Z. Horvat, Sandra P. D’Angelo, Mark A. Dickson and Nelly G. Adel and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

Parisa Momtaz

34 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

2015 808 citations Parisa Momtaz, Michael A. Postow et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Parisa Momtaz

Since Specialization

Citations

This map shows the geographic impact of Parisa Momtaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Parisa Momtaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Parisa Momtaz more than expected).

Fields of papers citing papers by Parisa Momtaz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Parisa Momtaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Parisa Momtaz. The network helps show where Parisa Momtaz may publish in the future.

Co-authorship network of co-authors of Parisa Momtaz

This figure shows the co-authorship network connecting the top 25 collaborators of Parisa Momtaz. A scholar is included among the top collaborators of Parisa Momtaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Parisa Momtaz. Parisa Momtaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade 2025 ·npj Precision Oncology ·(unknown), (unknown), (unknown), Martina Bradić, Barbara O’Malley, Irina Linkov, Edmund K. Bartlett, Parisa Momtaz, Kaled M. Alektiar, Mrinal M. Gounder, Evan Rosenbaum, William D. Tap, Sandra P. D’Angelo, Ciara M. Kelly	0
2	Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study 2024 ·Clinical Cancer Research ·James W. Smithy, (unknown), (unknown), Ronak Shah, Matthew Adamow, (unknown), (unknown), (unknown), (unknown), Alexander N. Shoushtari, Allison Betof Warner, Margaret K. Callahan, Parisa Momtaz, Omar Eton, Suresh Nair, Jedd D. Wolchok, Paul B. Chapman, Michael F. Berger, Katherine S. Panageas, Michael A. Postow	4
3	Germline pathogenic variants in a large convenience cohort of multiple melanoma subtypes. 2024 ·Journal of Clinical Oncology ·(unknown), Yelena Kemel, (unknown), James W. Smithy, Diana Mandelker, Parisa Momtaz, Walid K. Chatila, Nikolaus Schultz, Michael A. Postow, Zsofia K. Stadler, Alexander N. Shoushtari	1
4	A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma. 2024 ·Journal of Clinical Oncology ·James W. Smithy, Parisa Momtaz, Alexander N. Shoushtari, Jeeban Paul Das, Cecilia Lezcano, Suresh Nair, (unknown), Monica F. Chen, Katherine S. Panageas, Michael A. Postow	0
5	Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT). 2023 ·Journal of Clinical Oncology ·James W. Smithy, (unknown), (unknown), Colleen Maher, (unknown), (unknown), Alexander N. Shoushtari, Allison Betof Warner, Margaret K. Callahan, Parisa Momtaz, Omar Eton, Suresh Nair, Jedd D. Wolchok, Paul B. Chapman, Katherine S. Panageas, Michael A. Postow	0
6	Abstract PR012: Novel strategy for RAS-pathway targeting: Initial results from a phase 1b/2 clinical trial of the oral HDAC inhibitor bocodepsin (OKI-179) combined with binimetinib in patients with RAS-pathway mutated solid tumors and NRAS-mutated melanoma 2023 ·Molecular Cancer Therapeutics ·Rodabe N. Amaria, (unknown), Katy K. Tsai, Robert Galamaga, Parisa Momtaz, Evan Pisick, (unknown), Harish P. Dave, Duncan Walker, Jennifer R. Diamond, Kevin Litwiler, Ryan J. Sullivan	1
7	Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy 2023 ·The Oncologist ·Thomas M. Atkinson, Jennifer L. Hay, Soo Young Kim, Elizabeth Schofield, Michael A. Postow, Parisa Momtaz, Allison Betof Warner, Alexander N. Shoushtari, Margaret K. Callahan, Jedd D. Wolchok, Yuelin Li, Paul B. Chapman	6
8	Beyond the 5‐year milestone: Long‐term survivorship of melanoma patients treated off‐trial with anti‐PD‐1 2023 ·Pigment Cell & Melanoma Research ·Kimberly Loo, (unknown), Katherine S. Panageas, Margaret K. Callahan, Paul B. Chapman, Parisa Momtaz, Alexander N. Shoushtari, Jedd D. Wolchok, Michael A. Postow, Allison Betof Warner	1
9	Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB). 2021 ·Journal of Clinical Oncology ·Kimberly Loo, Debra A. Goldman, Katherine S. Panageas, Margaret K. Callahan, Paul B. Chapman, Parisa Momtaz, Alexander N. Shoushtari, Jedd D. Wolchok, Michael A. Postow, Allison Betof Warner	5
10	A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy. 2020 ·Journal of Clinical Oncology ·Michael A. Postow, Debra A. Goldman, Alexander N. Shoushtari, Allison Betof Warner, Margaret K. Callahan, Parisa Momtaz, (unknown), Omar Eton, Suresh Nair, Jedd D. Wolchok, Katherine S. Panageas, Paul B. Chapman	11
11	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade 2019 ·Annals of Surgical Oncology ·Danielle M. Bello, Katherine S. Panageas, Travis J. Hollmann, Alexander N. Shoushtari, Parisa Momtaz, Paul B. Chapman, Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok, Mary S. Brady, Daniel G. Coit, Charlotte E. Ariyan	36
12	First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA). 2019 ·Journal of Clinical Oncology ·Yelena Y. Janjigian, Joanne F. Chou, Marc Simmons, Parisa Momtaz, Francisco Sánchez-Vega, Marina Shcherba, Geoffrey Y. Ku, Elizabeth Won, Curtis R. Chong, Hans Gerdes, David P. Kelsen, David H. Ilson, (unknown), Michal Segal, Brittanie M Millang, Nikolaus Schultz, Pari Shah, David B. Solit, Marinela Capanu, Jaclyn F. Hechtman	44
13	First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma 2019 ·Annals of Oncology ·Yelena Y. Janjigian, Steven B. Maron, Joanne F. Chou, (unknown), Marc Simmons, Parisa Momtaz, Marina Shcherba, Geoffrey Y. Ku, Elizabeth Won, Francisco Sánchez-Vega, Hans Gerdes, David P. Kelsen, David H. Ilson, D. Solit, Nikolaus Schultz, Pari Shah, Marinela Capanu, Jaclyn F. Hechtman, Michelle F. Lamendola-Essel	8
14	PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma 2017 ·JCO Precision Oncology ·Federica Catalanotti, Donavan T. Cheng, Alexander N. Shoushtari, Douglas B. Johnson, Katherine S. Panageas, Parisa Momtaz, Catherine Higham, Helen Won, James J. Harding, Taha Merghoub, Neal Rosen, Jeffrey A. Sosman, Michael F. Berger, Paul B. Chapman, David B. Solit	49
15	Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor. 2017 ·Journal of Clinical Oncology ·Kimberly M. Komatsubara, Alexander N. Shoushtari, Sapna P. Patel, Parisa Momtaz, (unknown), Amanda Carter, (unknown), (unknown), (unknown), (unknown), (unknown), Grazia Ambrosini, (unknown), Gary K. Schwartz, Richard D. Carvajal	2
16	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation 2017 ·Oncotarget ·Parisa Momtaz, James J. Harding, Charlotte E. Ariyan, Daniel G. Coit, Taha Merghoub, Billel Gasmi, Daoqi You, Agnès Viale, Katherine S. Panageas, Aliaksandra Samoila, Michael A. Postow, Jedd D. Wolchok, Paul B. Chapman	6
17	Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone. 2016 ·Journal of Clinical Oncology ·Michael A. Postow, Deborah Kuk, Matthew Adamow, Cristina Carrera, Phillip Wong, Michael A. Curran, Claire F. Friedman, Parisa Momtaz, Alexander N. Shoushtari, Jedd D. Wolchok, Paul B. Chapman, Margaret K. Callahan	2
18	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies 2016 ·Oncotarget ·Parisa Momtaz, Elena Pentsova, Omar Abdel‐Wahab, Eli L. Diamond, David M. Hyman, Taha Merghoub, Daoqi You, Billel Gasmi, Agnès Viale, Paul B. Chapman	52
19	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway 2014 ·Pharmacogenomics and Personalized Medicine ·Michael A. Postow, Parisa Momtaz	93
20	Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment 2003 ·Current Opinion in Hematology ·Martha Wadleigh, Vincent T. Ho, Parisa Momtaz, Paul G. Richardson	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact